These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38755413)

  • 1. Upregulation of Immune checkpoint PD-L1 in Colon cancer cell lines and activation of T cells by Leuconostoc mesenteroides.
    Altves S; Guclu E; Yetisgin E; Bilecen K; Vural H
    World J Microbiol Biotechnol; 2024 May; 40(7):204. PubMed ID: 38755413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
    Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
    Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orexin A Suppresses the Expression of Exosomal PD-L1 in Colon Cancer and Promotes T Cell Activity by Inhibiting JAK2/STAT3 Signaling Pathway.
    Wen J; Chang X; Bai B; Gao Q; Zhao Y
    Dig Dis Sci; 2022 Jun; 67(6):2173-2181. PubMed ID: 34097168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.
    Yang W; Chen PW; Li H; Alizadeh H; Niederkorn JY
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2518-25. PubMed ID: 18296654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-γ.
    Wang H; Yan Z; Hao J; Yang B; Wang J; Yi L; Wang X; Li S; Zhang H; Zhang S
    Thorac Cancer; 2019 Dec; 10(12):2225-2235. PubMed ID: 31625289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 9. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.
    Porichis F; Hart MG; Zupkosky J; Barblu L; Kwon DS; McMullen A; Brennan T; Ahmed R; Freeman GJ; Kavanagh DG; Kaufmann DE
    J Virol; 2014 Mar; 88(5):2508-18. PubMed ID: 24352453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells.
    Feng J; Yang H; Zhang Y; Wei H; Zhu Z; Zhu B; Yang M; Cao W; Wang L; Wu Z
    Oncogene; 2017 Oct; 36(42):5829-5839. PubMed ID: 28604752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
    Coombs MRP; Harrison ME; Hoskin DW
    Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
    Xu L; Zhang Y; Tian K; Chen X; Zhang R; Mu X; Wu Y; Wang D; Wang S; Liu F; Wang T; Zhang J; Liu S; Zhang Y; Tu C; Liu H
    J Exp Clin Cancer Res; 2018 Oct; 37(1):261. PubMed ID: 30373602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
    Knopf P; Stowbur D; Hoffmann SHL; Hermann N; Maurer A; Bucher V; Poxleitner M; Tako B; Sonanini D; Krishnamachary B; Sinharay S; Fehrenbacher B; Gonzalez-Menendez I; Reckmann F; Bomze D; Flatz L; Kramer D; Schaller M; Forchhammer S; Bhujwalla ZM; Quintanilla-Martinez L; Schulze-Osthoff K; Pagel MD; Fransen MF; Röcken M; Martins AF; Pichler BJ; Ghoreschi K; Kneilling M
    Mol Cancer; 2023 Dec; 22(1):207. PubMed ID: 38102680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
    Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I
    Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
    Cai X; Wei B; Li L; Chen X; Liu W; Cui J; Lin Y; Sun Y; Xu Q; Guo W; Gu Y
    Int Immunopharmacol; 2020 Nov; 88():106858. PubMed ID: 32795895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human cytomegalovirus UL23 exploits PD-L1 inhibitory signaling pathway to evade T cell-mediated cytotoxicity.
    Yuan Q; Fan Z; Huang W; Huo X; Yang X; Ran Y; Chen J; Li H
    mBio; 2024 Jul; 15(7):e0119124. PubMed ID: 38829126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of immune checkpoint regulators in interferon γ induced urothelial carcinoma and activated T-lymphocyte cells by cytostatics.
    Hänze J; Schulte-Herbrüggen J; Hofmann R; Hegele A
    Genes Immun; 2023 Jun; 24(3):149-153. PubMed ID: 37138100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.